Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication

United Kingdom News News

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication
United Kingdom Latest News,United Kingdom Headlines
  • 📰 sdut
  • ⏱ Reading Time:
  • 26 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 95%

Federal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD

Federal health advisers are weighing the first-of-a-kind approval of

, which could set the stage for federal approval later this summer, though the FDA isn't required to follow the group's recommendations. highlights the challenges of studying and assessing psychedelic drugs. “This application is both consequential and complex,” FDA reviewer Dr. Tiffany R. Farchione said at the beginning of Tuesday's meeting. Because

is also associated with increased blood pressure. Because of those risks, the FDA has proposed strict limits on how and where

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

sdut /  🏆 5. in US

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationPsychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »

FDA panel to evaluate psychedelic MDMA for treatment of PTSD for first timeFDA panel to evaluate psychedelic MDMA for treatment of PTSD for first timeThe U.S. Food and Drug Administration held a meeting to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder for the first time.
Read more »

Psychedelic drug MDMA faces questions as FDA considers approval for PTSDPsychedelic drug MDMA faces questions as FDA considers approval for PTSDFederal health regulators are questioning the safety and evidence behind the first bid to use MDMA, the mind-altering club drug, as a treatment for PTSD, part of a decadeslong effort by advocates to move psychedelic drugs into the medical mainstream.
Read more »

Psychedelic drug MDMA faces questions as FDA considers approval for PTSDPsychedelic drug MDMA faces questions as FDA considers approval for PTSDFederal health regulators are questioning the safety and evidence behind the first bid to use MDMA, the mind-altering club drug, as a treatment for PTSD, part of a decadeslong effort by advocates to move psychedelic drugs into the medical mainstream.
Read more »

Psychedelic drug MDMA faces questions as FDA considers approval for PTSDPsychedelic drug MDMA faces questions as FDA considers approval for PTSDThe drug application is part of a decade-long effort by advocates to move psychedelic drugs into the medical mainstream. 
Read more »

Psychedelic drug MDMA faces questions as FDA considers approval for PTSDPsychedelic drug MDMA faces questions as FDA considers approval for PTSDFederal health regulators are set to review the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »



Render Time: 2025-04-07 04:17:43